Lasofoxifene

Known as: (-)-cis-5,6,7,8-tetrahydro-6-phenyl-5-(p-(2-(1-pyrrolidinyl)ethoxy)phenyl)-2-naphthol 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
BACKGROUND Tamoxifen and raloxifene reduce the risk of breast cancer in women at elevated risk of disease, but the duration of… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2011
2011
OBJECTIVE The aim of this study was to establish the gynecological effects of 5 years of treatment with lasofoxifene versus… (More)
Is this relevant?
Highly Cited
2010
2010
2010
BACKGROUND The effects of lasofoxifene on the risk of fractures, breast cancer, and cardiovascular disease are uncertain… (More)
  • table 1
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2006
2006
OBJECTIVE Osteoporosis is a significant health problem in postmenopausal women. Consequently, new and effective therapies are… (More)
Is this relevant?
Review
2006
Review
2006
The estrogen receptor alpha (ERalpha) has proven to be the single most important target in breast cancer over the last 30 years… (More)
Is this relevant?
Review
2006
Review
2006
Selective estrogen receptor modulators (SERMs) are structurally different compounds that interact with intracellular estrogen… (More)
Is this relevant?
Review
2005
Review
2005
Pfizer is developing lasofoxifene, an oral naphthalene derivative selective estrogen receptor modulator identified under a… (More)
Is this relevant?
2004
2004
The purpose of this study was to determine the long-term effects of lasofoxifene, a new selective estrogen receptor modulator, on… (More)
Is this relevant?
2000
2000
It has been well documented that selective estrogen receptor modulators (SERMs) can prevent bone loss in ovariectomized rats and… (More)
Is this relevant?